Catalog

Search by Category
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Contains 2 Component(s)

    On May 22, 2024 the MRF held an Ask the Expert webinar with Dr. Arlene Ruiz de Luzuriaga, Vice-Chief for Dermatopathology Operations, University of Chicago Medicine. This session was titled "Shining a Light on Sun Safety and Early Detecting of Melanoma" and explored the critical topic of sun safety and early detection of melanoma. The presentation discussed insights and practical tips on how to safeguard your skin from the sun's harmful rays and the importance of early detection in preventing melanoma. From understanding UV exposure to recognizing suspicious moles, this webinar will equip you with the knowledge and tools to prioritize the health of your skin. *This presentation was recorded

    image

    Dr. Ruiz de Luzuriaga

    Vice-Chief for Dermatopathology Operations

    The University of Chicago Medicine

    Dr. Ruiz de Luzuriaga is a board certified dermatologistand dermatopathologist. She is interested in epidemiologic studies in dermatology anddermatopathology, clinical informatics, and the use of information technology for theimprovement of patient care, diagnosis and treatment algorithms, quality improvement,and medical education. Her clinical focus is on total body photography, dermatoscopy,skin cancer surveillance, and melanoma prevention and early detection. She hopes toexplore the decision-making experience surrounding ambiguous melanocytic neoplasms, andhow patients and dermatologists incorporate additional data from novelancillary diagnostic tests for melanocytic lesions.

    Jeffrey Whitridge

    Patient Advocate

    Jeffrey Whitridge is a medical professional that works in the field of nutrition.  He has been practicing clinical nutrition and dietetics for over 25 years.  Jeffrey has been monitoring and surveilling his skin and mole integrity for over 20 years.  Jeffrey enjoys being active, travel and of course eats a plant forward diet.

  • Contains 2 Component(s)

    Learn more about the latest in melanoma diagnosis, treatment, and supportive care from experts at Robert H. Lurie Comprehensive Cancer Center. *This presentation was recorded in 2024.

    image
  • Contains 2 Component(s)

    On March 19, 2024 the MRF held an Ask the Expert webinar with Dr. 1. Allison Betof Warner, MD, PhD from Stanford University School of Medicine. This session was titled "TIL Cell Therapy - A Review of the Newest FDA Approved Drug for Advanced Melanoma" and took a deep dive look into TIL Cell Therapy, the newest groundbreaking treatment for advanced melanoma. During the webinar, patients and caregivers learned about the efficacy, durability, process and timeframe of this new FDA-approved treatment. The webinar also featured patient advocate Jamie Tomasko, who shared his experience with TIL Cell Therapy. *This presentation was recorded

    image

    Dr. Harriet Kluger

    Harvey and Kate Cushing Professor of Medicine in Oncology

    Yale Cancer Center

    Dr. Allison Betof Warner is Director of the Melanoma Program, Director of Solid Tumor Cellular Therapy, and Mark & Mary Stevens Endowed Scholar in Melanoma at Stanford Cancer Institute. Dr. Betof completed her MD and PhD at Duke University, Internal Medicine residency at Massachusetts General Hospital (Harvard University) and Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Betof’s laboratory focuses on understanding resistance to immune checkpoint blockade and cellular therapies for melanoma and other solid tumors. She is the Principal Investigator of clinical trials exploring novel treatments for immunotherapy-refractory melanoma and is internationally recognized for her expertise in brain/CNS metastasis and the use of novel cellular therapies. Dr. Betof has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy for the treatment of melanoma and other solid tumors. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), and Melanoma Research Foundation.

    Jennifer Ficko

    Patient Advocate

    Jamie lives in Tampa, Florida with his wife Angie. They have one son, Eric, a wonderful daughter in law Amy, and a beautiful 14 year old granddaughter.

    Jamie had surgery to remove melanoma from his back in 2012 and was diagnosed with Stage 4B Metastatic Melanoma in 2014. He was accepted to the Stage 2 TIL Trial at Moffitt cancer Center in Tampa, Florida. Jamie’s tumors continue to recede and grow smaller and some have completely disappeared with nothing left but scar tissue. He has not had a bad check up since he started the TIL Trial in 2014. Jamie credits TIL, the incredible staff at Moffitt and his wonderful family for saving his life. 

  • Contains 2 Component(s)

    On February 15, 2024 the MRF held an Ask the Expert webinar with Dr. Harriet Kluger from the Harvey and Kate Cushing Professor of Medicine in Oncology, Yale Cancer Center. This session was titled "The Current State and Evolution of Immunotherapy Treatment in Melanoma" and explored the trials that led to improvement in survival in melanoma patients with metastatic disease and the drugs that have been approved in recent years and associated side effects. The webinar also featured patient advocate Jennifer Ficko, who shared her experience with immunotherapy. *This presentation was recorded

    image

    Dr. Harriet Kluger

    Harvey and Kate Cushing Professor of Medicine in Oncology

    Yale Cancer Center

    Dr. Allison Betof Warner is Director of the Melanoma Program, Director of Solid Tumor Cellular Therapy, and Mark & Mary Stevens Endowed Scholar in Melanoma at Stanford Cancer Institute. Dr. Betof completed her MD and PhD at Duke University, Internal Medicine residency at Massachusetts General Hospital (Harvard University) and Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Betof’s laboratory focuses on understanding resistance to immune checkpoint blockade and cellular therapies for melanoma and other solid tumors. She is the Principal Investigator of clinical trials exploring novel treatments for immunotherapy-refractory melanoma and is internationally recognized for her expertise in brain/CNS metastasis and the use of novel cellular therapies. Dr. Betof has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy for the treatment of melanoma and other solid tumors. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), and Melanoma Research Foundation.

    Jennifer Ficko

    Patient Advocate

    Jamie lives in Tampa, Florida with his wife Angie. They have one son, Eric, a wonderful daughter in law Amy, and a beautiful 14 year old granddaughter.

    Jamie had surgery to remove melanoma from his back in 2012 and was diagnosed with Stage 4B Metastatic Melanoma in 2014. He was accepted to the Stage 2 TIL Trial at Moffitt cancer Center in Tampa, Florida. Jamie’s tumors continue to recede and grow smaller and some have completely disappeared with nothing left but scar tissue. He has not had a bad check up since he started the TIL Trial in 2014. Jamie credits TIL, the incredible staff at Moffitt and his wonderful family for saving his life. 

  • Contains 2 Component(s)

    On January 30, 2024 the MRF held an Ask the Expert webinar with Dr. Gino K. In, a medical oncologist at the University of Southern California Norris Comprehensive Cancer Center. This session was titled "Oncolytic Viral Therapies in the Treatment of Melanoma and Skin Cancers" and explored the mechanisms of how oncolytic viruses work against cancer, the new approaches to the design of these drugs, and how these viruses are designed to minimize the risk of infection. The webinar also featured patient advocates and Donna Soskin and Jim Day who shared their experience with Oncolytic Therapy. *This presentation was recorded

    image

    Donna Soskin

    Melanoma Survivor

    Donna is a retired masseuse and former Pilates teacher. Donna is a mother of two grown adult children. She is crazy about the NFL, enjoys playing tennis and watching sports. Donna is a melanoma survivor.

    Jim Day

    Melanoma Survivor

    Jim Day is an artist and custom fabricator from Los Angeles. He is well known in his community as the guy who can build anything out of anything, and often helps others build things they could not build themselves. In 2021, Jim discovery he had a brain tumor, and was diagnosed with Stage 4 metastatic melanoma. After his diagnosis, Jim met with Dr. In whom informed him of his treatment options. Jim knew instantly when he spoke to Dr. In about oncolytic viruses that he wanted to work with him. Two years later Jim has lost an extraordinary amount of cancer, and his side effects are minimal. Jim says that because of Dr. In and the oncolytic virus therapies, he feels alive again. 

    Dr. Gino In

    medical oncologist

    University of Southern California

    Gino K. In is a medical oncologist at the University of Southern California, who specializes in solid tumor and cutaneous oncology. He completed his oncology fellowship at the USC Keck School of Medicine and subsequently joined the USC Norris Comprehensive Cancer Center, where he oversees the multidisciplinary melanoma and skin cancer program, and leads clinical trials for melanoma, and other skin cancers, including cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma.

  • Contains 2 Component(s)

    Learn more about the latest in melanoma diagnosis, treatment, survivorship, and prevention from experts during this virtual MRF patient symposia. *This presentation was recorded in 2023.

    image

    Rebecca Hartman, MD, MPH

    Melanoma Research Foundation

    Dr.Rebecca Hartman is Associate Chief of the Dermatology section at VA BostonHealthcare System, Director of Melanoma Epidemiology at Brigham and Women’sHospital, and Assistant Professor of Dermatology at Harvard Medical School. Sheclinically specializes in caring for patients with melanoma and pigmentedlesions at Dana Farber Cancer Institute and practices medical dermatology at VABoston. In addition, she conducts melanoma epidemiologic and clinical researchfunded by the VA and Department of Defense, focusing on aggressive and raremelanomas.

    Tara Mitchell, MD

    Melanoma Research Foundation

    Dr. Tara Mitchell is an Associate Professor of medicine at the University of Pennsylvania’s Perelman School of Medicine. She is the Section Chief of melanoma/sarcoma in the division of Hematology/Oncology at Penn's Abramson Cancer Center and the Director of Clinical Research for the Tara Miller Melanoma Center at Penn. Dr. Mitchell is board certified in both medical oncology and clinical pharmacology.

    Vernon Sondak, MD

    Chair, Department of Cutaneous Oncology

    Moffitt Cancer Center

    Dr. Sondak is Chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. He holds the Richard M. Schulze Family Foundation Distinguished Endowed Chair in Cutaneous Oncology, and is also a Professor in the Departments of Oncologic Sciences and Surgery at the University of South Florida Morsani College of Medicine. Since 2004, when he came to Tampa, the Cutaneous Oncology Clinic at Moffitt has grown into one of the largest multidisciplinary treatment centers for pediatric melanoma and related conditions in the world. Dr. Sondak has been a leader in studies of surgical treatment of melanoma and other cutaneous malignancies, particularly in the application of sentinel lymph node biopsy and lymph node dissection to the staging and treatment of melanoma, and has been instrumental in training many surgical oncologists in these techniques over the years. Dr. Sondak also has a strong research background: he served as Principal Investigator of the Moffitt Skin SPORE, a major NCI-funded “team science” grant conducting translational research in melanoma and other cutaneous malignancies. His research interests include surgical treatment of melanoma in adults and children; adjuvant (postoperative) and neoadjuvant (preoperative) therapy of melanoma; and evaluation of new therapies for patients with localized or disseminated melanoma.

    Evan J. Wuthrick, MD

    Dr. Wuthrick is an Associate Member in radiation oncology at Moffitt Cancer Center and the Section Head for Cutaneous Radiation Oncology with clinical and research interests centered around cutaneous malignancies.  Dr. Wuthrick is the clinical director of radiation oncology at Moffitt Cancer, associate chair of Graduate Medical Education at Moffitt, and Chair of the NRG Oncology Radiation Oncology Committee.

  • Contains 2 Component(s)

    On September 18, 2023 the MRF held an Ask the Expert webinar with Dr. Correa-Selm, Associate Professor of the Department of Dermatology at Morsani School of Medicine in the University of South Florida, and member of the Cutaneous Oncology Team at Moffitt Cancer Center. This session was titled" Melanoma in the Hispanic Population" and featured patient advocate, Jose Gonzalez. They spoke about the importance of skin care and sun protection in the Hispanic community. *This presentation was recorded in 2023.

    image

    Dr. Harriet Kluger

    Harvey and Kate Cushing Professor of Medicine in Oncology

    Yale Cancer Center

    Dr. Kluger is an internationally recognized expert on the disease she treats - melanoma and renal cell carcinoma (RCC). She engages in clinical and bench-based translational research, with a focus on developing novel therapies. Her lab has been continuously NIH-funded, and she has published in top-tier journals. She designs clinical trials with laboratory correlates resulting from her pre-clinical work, and she has been heavily involved in early phase development of immunotherapy regimens.

  • Contains 2 Component(s)

    On August 29th, the MRF held an informative discussion featuring Dr. Alan Tan, Director of the genitourinary oncology program at Rush University medical center and co-leader of the precision medicine program to educate patients and the community on tumor-informed ctDNA as an option for residual disease detection, treatment response monitoring, and surveillance. *This presentation was recorded in 2023.

    image

    Dr. Alan Tan

    Director of Genitourinary Oncology Program & Co-Lead of the Precision Medicine Program Rush University Medical Center

    Dr. Alan Tan is director of the genitourinary oncology program at Rush University medical center and co-leads the precision medicine program.  He is co-chair of the Hoosier cancer research network melanoma working group.  He also serves as the genitourinary executive officer for the Alliance for Clinical Trials in Oncology.  His research interests include biomarker development for melanoma and genitourinary malignancies.

  • Contains 3 Component(s)

    Learn more about the latest in melanoma diagnosis, treatment, survivorship, and prevention from experts at UNC Lineberger Comprehensive Cancer Center *This presentation was recorded in 2023.

    image
  • Contains 2 Component(s)

    On July 24, the MRF held an informative discussion featuring Dr. Michael A. Postow, Chief, Melanoma Service, Co-Director, Melanoma Disease Management Team and Associate Attending Physician from Memorial Sloan Kettering Cancer Center and patient advocate and panelist Bennie Lunsford. Special thanks #Replimune for sponsoring this important educational opportunity. *This presentation was recorded in 2023.

    image

    Michael A. Postow, MD

    Chief, Melanoma Service, Associate Attending Physician

    Memorial Sloan Kettering Cancer Center

    Michael Postow is a medical oncologist and the Chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center. He led the first randomized trial of combination immune checkpoint inhibition (nivolumab + ipilimumab), resulting in its FDA approval. He has also written and presented on topics related to immunotherapy outcomes and side effects and studied new ways to combine immunotherapy with local treatments (i.e. radiation).  His completed and ongoing work continue to impact cancer patients and advance immunotherapy for melanoma and other diseases. He enjoys skiing, outdoor activities, and trying to keep up with his two toddlers and triathlete wife.

    Bennie Lunsford

    Bennie Lunsford has had stage 4 cancer since 2013 and was stage 2 in 2005. He has pretty much done almost all the treatments you can think of. He has a wife, Janet, that he owes his reason for still being here. She was the one that was instrumental in finding the trial and treatments that allow him to be here today. Bennie has two children, Colby who is 13 and Emmi who is 16. He lives in Houston, Texas and is the IT Director for an engineering firm.